These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21796479)

  • 41. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.
    Park SH; Kim BI; Yun JW; Kim JW; Park DI; Cho YK; Sung IK; Park CY; Sohn CI; Jeon WK; Kim H; Rhee EJ; Lee WY; Kim SW
    J Gastroenterol Hepatol; 2004 Jun; 19(6):694-8. PubMed ID: 15151626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population.
    Cho HC
    Gut Liver; 2016 Jan; 10(1):117-25. PubMed ID: 26260755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
    Hu H; Wang J; Li X; Shen L; Shi D; Meng J
    Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects.
    Preuss HG; Kaats GR; Mrvichin N; Swaroop A; Bagchi D; Clouatre D; Preuss JM
    J Am Coll Nutr; 2018 Aug; 37(6):457-465. PubMed ID: 29652564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels.
    Kim KS; Oh HJ; Kim DJ; Kim SK; Park SW; Cho YW; Huh KB
    Endocr J; 2013; 60(12):1295-301. PubMed ID: 24047563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures.
    Zelber-Sagi S; Nitzan-Kaluski D; Halpern Z; Oren R
    Liver Int; 2006 Sep; 26(7):856-63. PubMed ID: 16911469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.
    Martin-Rodriguez JL; Gonzalez-Cantero J; Gonzalez-Cantero A; Arrebola JP; Gonzalez-Calvin JL
    Medicine (Baltimore); 2017 Apr; 96(17):e6770. PubMed ID: 28445310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The influence of insulin resistance in the occurence of non-alcoholic fatty liver disease among first degree relatives of type 2 diabetes.
    Hazim A; Purnamasari D; Kalista KF; Lesmana CRA; Nugroho P
    Diabetes Metab Syndr; 2019; 13(2):1431-1435. PubMed ID: 31336502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Non-alcoholic fatty liver, high sensitivity C reactive protein and insulin resistance].
    Zhou WD; Yang YL; Che ZH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):565-70. PubMed ID: 18667766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men.
    Park SH; Kim BI; Kim SH; Kim HJ; Park DI; Cho YK; Sung IK; Sohn CI; Kim H; Keum DK; Kim HD; Park JH; Kang JH; Jeon WK
    J Am Coll Nutr; 2007 Aug; 26(4):321-6. PubMed ID: 17906183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gender-specific differences in clinical and metabolic variables associated with NAFLD in a Mexican pediatric population.
    Villanueva-Ortega E; Garcés-Hernández MJ; Herrera-Rosas A; López-Alvarenga JC; Laresgoiti-Servitje E; Escobedo G; Queipo G; Cuevas-Covarrubias S; Garibay-Nieto GN
    Ann Hepatol; 2019; 18(5):693-700. PubMed ID: 31151875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
    Enjoji M; Kotoh K; Kato M; Higuchi N; Kohjima M; Nakashima M; Nakamuta M
    Int J Mol Med; 2008 Oct; 22(4):521-7. PubMed ID: 18813860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.
    Pirgon O; Cekmez F; Bilgin H; Eren E; Dundar B
    Obes Res Clin Pract; 2013; 7(4):e275-83. PubMed ID: 24306155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease.
    Ivancovsky-Wajcman D; Zelber-Sagi S; Fliss Isakov N; Webb M; Zemel M; Shibolet O; Kariv R
    Clin Transl Gastroenterol; 2019 May; 10(5):1-10. PubMed ID: 31082855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
    Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
    J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study].
    Zheng RH; Ding CF
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):98-101. PubMed ID: 18683746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of non-alcoholic fatty liver disease in obese children.
    Sartorio A; Del Col A; Agosti F; Mazzilli G; Bellentani S; Tiribelli C; Bedogni G
    Eur J Clin Nutr; 2007 Jul; 61(7):877-83. PubMed ID: 17151586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.
    Zhang S; Du T; Zhang J; Lu H; Lin X; Xie J; Yang Y; Yu X
    Lipids Health Dis; 2017 Jan; 16(1):15. PubMed ID: 28103934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.